NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Includes thermostabilized Ebola vaccines
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Subscribe To Our Newsletter & Stay Updated
